Document Detail


Pharmacogenetic tests: the need for a level playing field.
MedLine Citation:
PMID:  23274456     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The delivery of more personalized medicinecould be accelerated by addressing the substantial differences in the level of evidence required for the inclusion of pharmacogenetic tests in treatment guidelines, drug labelling and reimbursement schemes compared with that needed for non-genetic diagnostic tests.
Authors:
Munir Pirmohamed; Dyfrig A Hughes
Related Documents :
6867796 - Two-step tuberculin testing in a veterans domiciliary population.
15610806 - Diagnosis of tuberculosis in south african children with a t-cell-based assay: a prospe...
11463236 - Bovigam: an in vitro cellular diagnostic test for bovine tuberculosis.
2023716 - Binocular accommodative facility in prepresbyopic adults and its relation to symptoms.
818896 - Counterelectrophoresis in the diagnosis of amebiasis.
17630216 - Validation of the indirect fluorescent antibody and the complement fixation tests for t...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  12     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  3-4     Citation Subset:  IM    
Affiliation:
Department of Molecular and Clinical Pharmacology, Wolfson Centre for Personalised Medicine, University of Liverpool, 1-5 Brownlow Street, Liverpool L69 3GL, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
Next Document:  Objective assessment of cancer genes for drug discovery.